In addition, PARPi increased the number of PD-L1 cells, and further studies confirmed that the combination of immune checkpoint blockade and PARPi (e.g., olaparib) increased the percentage of tumor-infiltrating CD8+ cells, suggesting the possibility that this combination therapy could synergically limit tumor growth and prolong survival[146, 147, 149]. Here, CD8A is linked to neoplasm.